Alzamend Neuro
ALZN
24 hedge funds and large institutions have $2.7M invested in Alzamend Neuro in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 8 closing their positions.
380% more call options, than puts
Call options by funds: $96K | Put options by funds: $20K
0% less ownership
Funds ownership: 0.01% → 0% (-0%)
23% less funds holding
Funds holding: 31 → 24 (-7)
33% less capital invested
Capital invested by funds: $4.04M → $2.7M (-$1.34M)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.77K |
| 2 |
VF
Virtu Financial
New York
|
+$3.01K |
| 3 |
HIA
Harbor Investment Advisory
Lutherville,
Maryland
|
+$752 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$752 |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$752 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$310K |
| 2 |
HF
HRT Financial
New York
|
-$32K |
| 3 |
Renaissance Technologies
New York
|
-$28K |
| 4 |
E
Ergoteles
New York
|
-$13.3K |
| 5 |
Two Sigma Investments
New York
|
-$10.9K |
ALZN Hedge Fund Activity: Q1 2023 in Review
24 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q1 2023, worth a combined $2.7M — down 33% from $4.04M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ALZN and 1 opened new positions — a net loss of 7 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $6.77K. The largest seller was Vanguard Group, cutting an estimated $310K.
- 24 institutional investors held Alzamend Neuro (ALZN) as of Q1 2023, down from 31 in Q4 2022.
- Funds reported $2.7M of Alzamend Neuro stock for Q1 2023, down 33% quarter-over-quarter.
- 1 fund opened new Alzamend Neuro positions in Q1 2023 and 8 closed out, a net change of -7 holders.
- The largest Alzamend Neuro buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $6.77K added.
- The largest Alzamend Neuro seller in Q1 2023 was Vanguard Group, an estimated $310K sold.
Based on aggregated 13F filings for Q1 2023.